BLUE - bluebird bio Says Its Drug Unlikely to Have Caused Blood Cancer
In February, bluebird bio (NASDAQ: BLUE) announced a temporary suspension of two clinical trials evaluating LentiGlobin, an experimental gene therapy, after a trial patient was diagnosed with acute myeloid leukemia (AML), a blood and bone marrow cancer. The possibility that a lentiviral vector used in Bluebird's drugs caused the cancer called into question the viability of its genetic program, causing a sharp sell-off in its shares.
Today, Bluebird unveiled updated results from its internal investigation, suggesting it's unlikely the AML case reported in its phase 1/2 (HGB-206) study of LentiGlobin for sickle cell disease (SCD) was caused by its lentiviral vector.
Image source: Getty Images.
For further details see:
bluebird bio Says Its Drug "Unlikely" to Have Caused Blood Cancer